ADDISON, Texas, Sept. 30, 2013 /PRNewswire/ -- ULURU Inc.
(OTCQB: ULUR), today announced the expansion of the
Altrazeal® international marketing network to include
Scandinavia and Finland.
Marketing and distribution agreements have been signed with
companies with extensive wound care experience to exclusively
distribute Altrazeal® in these territories. It is
anticipated that the initial product shipment will be made in the
fourth quarter 2013.
Commenting on the extension of the international marketing
network, Helmut Kerschbaumer,
Managing Director of Altrazeal GmbH, stated, "This represents a
continuation of our strategy of appointing highly qualified
companies throughout the territory to exclusively market and
distribute Altrazeal®. Significant activities have
already been completed within the Scandinavian and Finnish markets
including extensive training of company representatives and opinion
leaders. I am very confident that our outstanding partners will
successfully establish Altrazeal® as a leading product
in these markets."
Altrazeal® is a scientifically engineered advanced
wound dressing designed to incorporate the desired features and
benefits of the ideal wound dressing. Altrazeal®
competes in the advanced wound dressing market which, worldwide, is
estimated to be $6.5 billion growing
annually at 13%. Altrazeal® has demonstrated potential
clinical and economic advantages in a number of chronic and acute
wounds including diabetic foot ulcers, venous leg ulcers and
geriatric wounds.
Commenting on the expansion of the international marketing
network, Kerry P. Gray, President
and CEO of ULURU, stated, "We are very pleased with the progress
Altrazeal GmbH has made securing experienced marketing partners
throughout the territory. The interest companies have expressed,
throughout the territory, to marketing Altrazeal®
clearly validates the market potential of Altrazeal®, a
cost effective alternative in the advanced wound care
market."
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused
on the development of a portfolio of wound management and oral care
products to provide patients and consumers improved clinical
outcomes through controlled delivery utilizing its innovative
Nanoflex® Aggregate technology and OraDisc™ transmucosal
delivery system. For further information about ULURU Inc.,
please visit our website at www.ULURUinc.com. For further
information about Altrazeal®, please visit
www.Altrazeal.com.
This press release contains certain statements that are
forward-looking within the meaning of Section 27a of the Securities
Act of 1933, as amended. These statements are subject to
numerous risks and uncertainties, including but not limited to the
launch of Altrazeal® in the territory, the
commercial potential of Altrazeal®, the interest of
companies throughout the territory and the demonstration of cost
savings and clinical benefits, and the risk factors detailed in the
Company's Annual Report on Form 10-K for the year ended
December 31, 2012, and other reports
filed by us with the Securities and Exchange Commission.
Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145
SOURCE ULURU Inc.